VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study.
Saved in:
| Title: | VP5-2024: Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. |
|---|---|
| Authors: | Metcalf, R.1 (AUTHOR), Laban, S.2 (AUTHOR), Kristensen, C.A.3 (AUTHOR), Ciuleanu, T-E.4 (AUTHOR), Braña, I.5 (AUTHOR), Soria Rivas, A.6 (AUTHOR), Dieter, S.M.7 (AUTHOR), Bols, A.8 (AUTHOR), Forster, M.D.9 (AUTHOR), Covela, M.R.10 (AUTHOR), Christian, J.11 (AUTHOR), Vogl, F.D.12 (AUTHOR), Mueller, C.12 (AUTHOR), Triebel, F.13 (AUTHOR) |
| Source: | Annals of Oncology. Aug2024, Vol. 35 Issue 8, p754-755. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.06.012 |
